CUMBERLAND PHARMACEUTICALS INC — Form 8-K
Filed July 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Cumberland Pharmaceuticals announced a special cash dividend of $1.50 per share (record date July 23, 2026; payment date July 31, 2026) funded by proceeds from its strategic transaction with Apotex Health Corp., which closed with $100M upfront cash plus up to $11M in contingent payments. The company also authorized a $5M share repurchase program and stated it will retain significant liquidity for product development, specifically ifetroban clinical programs in DMD cardiomyopathy, systemic sclerosis, IPF, and cancer metastasis.
Why this rating
Special dividend of $1.50/share represents substantial capital return on $29.4M market cap company; Apotex deal ($100M+) is transformational. However, company retains cash for pipeline. Material shareholder value event.
See more from July 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.